{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:43Z","timestamp":1787682463781,"version":"build-2784847793"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Limited evidence supports multigenetic pharmacogenomics\u2013guided treatment (MPGT) in schizophrenia.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the clinical effectiveness of MPGT in schizophrenia in a randomized clinical trial (RCT).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This RCT was conducted from March 2020 to March 2022. Male Chinese Han inpatients aged 18 to 60 years diagnosed with schizophrenia with a Positive and Negative Symptom Scale (PANSS) score of 60 or more from 2 selected study hospitals were included. Patients and raters were masked to MPGT or treatment as usual (TAU) randomization.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomly assigned in a 1:1 ratio to receive either MPGT or TAU for 12 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary efficacy outcome was the percentage change in PANSS total scores (range, 30 to 210) from baseline to week 6 analyzed by a modified intention-to-treat mixed model for repeated measures. The secondary outcome included response and symptomatic remission rates.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 210 participants (mean [SD] age, 29.2 [8.8] years) were enrolled and analyzed, with 113 assigned to MPGT and 97 to TAU. Compared with those randomized to TAU, participants randomized to MPGT demonstrated a significantly higher percentage change in PANSS score (74.2% vs 64.9%; adjusted mean difference, 9.2 percentage points; 95% CI, 4.4-14.1 percentage points; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and a higher response rate (93 of 113 [82.3%] vs 63 of 97 [64.9%]; adjusted odds ratio, 2.48; 95% CI, 1.28-4.80; P<\/jats:italic>\u2009=\u2009.01) at the end of week 6.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this RCT of MPGT, MPGT was more effective than TAU in treating patients with schizophrenia. These findings suggest that multigenetic pharmacogenomic testing could serve as an effective tool to guide the treatment of schizophrenia.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Chinese Clinical Trial Registry Identifier: ChiCTR2000029671<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.35518","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:31:04Z","timestamp":1696606264000},"page":"e2335518","source":"Crossref","is-referenced-by-count":28,"title":["Multigenetic Pharmacogenomics\u2013Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia"],"prefix":"10.1001","volume":"6","author":[{"given":"Zhewei","family":"Kang","sequence":"first","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qin","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Guizhou Province, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Sun","sequence":"additional","affiliation":[{"name":"Tangshan Mental Health Center, Tangshan Fifth Hospital, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Lu","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Shantou University Mental Health Center, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Feng","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyanan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[{"name":"Zhumadian Second People\u2019s Hospital, Zhumadian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Yue","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, Peking University Sixth Hospital, Beijing, China"},{"name":"National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Beijing, China"},{"name":"NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China"},{"name":"PKU-IDG\/McGovern Institute for Brain Research, Peking University, Beijing, China"},{"name":"Chinese Institute for Brain Research, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"issue":"6","key":"zoi231020r3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016.","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"issue":"1","key":"zoi231020r4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology.","volume":"34","author":"Barnes","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"11","key":"zoi231020r5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"9","key":"zoi231020r6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis.","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"zoi231020r7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"3","key":"zoi231020r8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.v17.3","article-title":"Management of common adverse effects of antipsychotic medications.","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"issue":"12","key":"zoi231020r9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi231020r10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41380-021-01340-6","article-title":"Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application.","volume":"27","author":"Murphy","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"zoi231020r11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41398-021-01600-7","article-title":"Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis.","volume":"11","author":"Virelli","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"3","key":"zoi231020r12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2217\/pme-2017-0094","article-title":"Analytical validation of a psychiatric pharmacogenomic test.","volume":"15","author":"Jablonski","year":"2018","journal-title":"Per Med"},{"issue":"7","key":"zoi231020r13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/jcph.v62.7","article-title":"Medication optimization using pharmacogenomic testing in a complex mental health population prescribed psychiatric polypharmacy.","volume":"62","author":"Wood","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"zoi231020r14","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.99","article-title":"Using a pharmacogenomic algorithm to guide the treatment of depression.","volume":"2","author":"Hall-Flavin","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"5","key":"zoi231020r15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/tpj.2014.85","article-title":"Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.","volume":"15","author":"Altar","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"zoi231020r16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study.","volume":"111","author":"Greden","year":"2019","journal-title":"J Psychiatr Res"},{"issue":"1","key":"zoi231020r17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"4","key":"zoi231020r18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/cts.v14.4","article-title":"Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial.","volume":"14","author":"Papastergiou","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"6","key":"zoi231020r19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry.","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"zoi231020r21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"11","key":"zoi231020r22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi231020r23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review.","volume":"172","author":"Samara","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"2-3","key":"zoi231020r24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"},{"issue":"3","key":"zoi231020r25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus.","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi231020r26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"issue":"1-2","key":"zoi231020r27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1081\/BIP-100104194","article-title":"Accounting for dropout bias using mixed-effects models.","volume":"11","author":"Mallinckrodt","year":"2001","journal-title":"J Biopharm Stat"},{"issue":"3","key":"zoi231020r28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/10543401003777995","article-title":"MMRM versus MI in dealing with missing data\u2013a comparison based on 25 NDA data sets.","volume":"21","author":"Siddiqui","year":"2011","journal-title":"J Biopharm Stat"},{"issue":"6","key":"zoi231020r30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing.","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"12","key":"zoi231020r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27909","article-title":"Effect of routine cytochrome P450 2D6 and 2C19 genotyping on antipsychotic drug persistence in patients with schizophrenia: a randomized clinical trial.","volume":"3","author":"J\u00fcrgens","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi231020r32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.psychres.2018.02.055","article-title":"Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.","volume":"279","author":"Walden","year":"2019","journal-title":"Psychiatry Res"},{"issue":"2","key":"zoi231020r33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41397-017-0004-2","article-title":"Cost-effectiveness of HLA-DQB1\/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.","volume":"19","author":"Girardin","year":"2019","journal-title":"Pharmacogenomics J"},{"key":"zoi231020r34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi231020r35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"key":"zoi231020r36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.schres.2017.10.018","article-title":"Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults.","volume":"195","author":"DeRosse","year":"2018","journal-title":"Schizophr Res"},{"issue":"4","key":"zoi231020r37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00406-003-0421-x","article-title":"Is executive function associated with symptom severity in schizophrenia?","volume":"253","author":"Simon MD","year":"2003","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"zoi231020r38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.psychres.2019.02.036","article-title":"Association between symptom control and functional improvement in patients with acute schizophrenia: a post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.","volume":"274","author":"Si","year":"2019","journal-title":"Psychiatry Res"},{"issue":"3","key":"zoi231020r39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.31887\/DCNS.2010.12.3\/mlambert","article-title":"Remission in schizophrenia: validity, frequency, predictors, and patients\u2019 perspective 5 years later.","volume":"12","author":"Lambert","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"zoi231020r40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/pcn.2019.73.issue-5","article-title":"The coming-of-age of pharmacogenetic testing in clinical psychiatry.","volume":"73","author":"Yoshida","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"zoi231020r41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.2339","article-title":"Pharmacogenetics-guided advances in antipsychotic treatment.","volume":"110","author":"Islam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"zoi231020r42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","article-title":"DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.","volume":"163","author":"Lencz","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"3","key":"zoi231020r43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000445295","article-title":"PDE7B, NMBR and EPM2A variants and schizophrenia: a case-control and pharmacogenetics study.","volume":"73","author":"Porcelli","year":"2016","journal-title":"Neuropsychobiology"},{"issue":"9","key":"zoi231020r44","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","article-title":"Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.","volume":"69","author":"Malhotra","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"zoi231020r46","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cpt.2019.105.issue-5","article-title":"Standardized biogeographic grouping system for annotating populations in pharmacogenetic research.","volume":"105","author":"Huddart","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"zoi231020r47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jmoldx.2021.05.013","article-title":"Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.","volume":"23","author":"Pratt","year":"2021","journal-title":"J Mol Diagn"},{"issue":"9","key":"zoi231020r48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","article-title":"CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.","volume":"25","author":"Pratt","year":"2023","journal-title":"J Mol Diagn"},{"key":"zoi231020r1","volume-title":"International Classification of Diseases, 11th Revision (ICD-11)","author":"World Health Organization","year":"2018"},{"key":"zoi231020r20","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","edition":"4th ed"},{"key":"zoi231020r2","unstructured":"World Health Organization. Schizophrenia. Assessed October 4, 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia"},{"key":"zoi231020r29","unstructured":"Brown? E, Shah? P, Kim? J, Boehm? F. chlorpromazineR: convert antipsychotic doses to chlorpromazine equivalents. Accessed October 4, 2022. https:\/\/docs.ropensci.org\/chlorpromazineR\/"},{"key":"zoi231020r45","unstructured":"PharmGKB. Gene-specific information tables for CYP2D6. Accessed August 1, 2023. https:\/\/www.pharmgkb.org\/page\/cyp2d6RefMaterials"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2810261\/kang_2023_oi_231020_1695845432.73463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:31:09Z","timestamp":1696606269000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2810261"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35518","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}